ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol Myers Squibb will team up with the synthetic biology and machine learning firm A-Alpha Bio to find targets for molecular glues, which are small molecules often used to join badly behaving proteins to enzymes that mark them for destruction. A-Alpha will identify enzymes and protein targets that could be ripe for gluing; BMS can use the pairings to develop molecular glues. A-Alpha will receive an up-front payment of an undisclosed amount and be eligible for milestones. BMS already has several molecular glue drugs approved or in clinical trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X